Nils G. Edvardsson
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Educational level and cardiovascular outcomes in patients hospitalized with first-detected atrial fibrillation: a Swedish nationwide cohort study.
Journal: BMC cardiovascular disorders
Published: April 20, 2026
The impact of education level on all-cause mortality in patients with atrial fibrillation.
Journal: Scientific reports
Published: March 25, 2024
Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial.
Journal: Nature medicine
Published: June 15, 2023
A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation.
Journal: British journal of clinical pharmacology
Published: July 05, 2022
All-cause mortality trends in patients hospitalized for atrial fibrillation in Sweden: Role of age, stroke risk, and education.
Journal: International journal of cardiology. Heart & vasculature
Published: April 27, 2022
The contribution of intermittent handheld electrocardiogram and continuous electrocardiogram monitoring with an implantable loop recorder to detect incident and recurrent atrial fibrillation during 1 year after coronary artery bypass graft surgery: A prospective cohort study.
Journal: Heart rhythm O2
Published: August 02, 2021
Inhibition of KCa2 Channels Decreased the Risk of Ventricular Arrhythmia in the Guinea Pig Heart During Induced Hypokalemia.
Journal: Frontiers in pharmacology
Published: February 26, 2020
First Clinical Study with AP30663 - a KCa 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation.
Journal: Clinical and translational science
Published: February 26, 2020
Inhibition of KCa2 and Kv11.1 Channels in Pigs With Left Ventricular Dysfunction.
Journal: Frontiers in pharmacology
Published: January 20, 2020
Characterization of Atrial and Ventricular Structural Remodeling in a Porcine Model of Atrial Fibrillation Induced by Atrial Tachypacing.
Journal: Frontiers in veterinary science
Published: December 26, 2019
The KCa2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs.
Journal: Frontiers in pharmacology
Published: December 16, 2019
Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.
Journal: Frontiers in pharmacology
Published: December 16, 2019
Last Updated: 09/26/2026